CHRS Stock — Coherus Oncology Inc.: Cash, EV, Pipeline

Share price

$1.35

Market cap

$208.6M

Cash

$105.3M

Enterprise value

$103.3M

Balance sheet

Cash	$105.3M
Debt	$0.0M
Net cash	$105.3M
Enterprise value	$103.3M
Basic shares	154.5M shares
Fully diluted shares	184.9M shares
Fully diluted market cap	$249.6M
Cash per share	$0.68

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CHRS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 11 - Dec 23	CHS-114	Phase 1	Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma	—
Oct 13 - Nov 24	Casdozokitug	Phase 2	Hepatocellular Carcinoma	2H 2026
Feb 9 - Mar 22	STC-15 monotherapy	Phase 2	Solid Tumor; Sarcoma; Leiomyosarcoma	—
Feb 12 - Mar 25	CHS-114	Phase 1	Metastatic Solid Tumor; Advanced Solid Tumor	—
Jul 11 - Aug 22	CHS-1000	Phase 1	Advanced or Metastatic Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LOQTORZI

Approved · Active Modality: anti-PD-1 monoclonal antibody

Aliases toripalimab-tpzi

Target PD-1

Partnerships Junshi Biosciences (co-development and commercialization, US/Canada); Apotex (Canada license)

Indications

nasopharyngeal carcinoma (NPC) (Approved)

Status note FDA-approved and marketed; launched in US January 2024; Health Canada approval October 2025.

Casdozokitug

Phase 2 · Active Modality: antagonist monoclonal antibody

Aliases CHS-388, SRF388

Target IL-27

Indications

hepatocellular carcinoma (Phase 2)
lung cancer (Phase 2)
renal cell carcinoma (Phase 2)

Status note Mid-stage clinical candidate; FDA orphan drug designation; global rights held by Coherus; no discontinuation disclosed.

Tagmokitug

Phase 1 · Active Modality: afucosylated IgG1 monoclonal antibody

Aliases CHS-114, SRF114

Target CCR8

Partnerships Vaccinex (worldwide exclusive license); Janssen (clinical supply agreement for pasritamig combination)

Indications

head and neck squamous cell carcinoma (Phase 1)
metastatic castration-resistant prostate cancer (with pasritamig) (Phase 1)

Status note Phase 1 enrolling in HNSCC with and without LOQTORZI; Phase 1b with pasritamig in mCRPC; global rights held by Coherus; no discontinuation disclosed.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Casdozokitug
Lead indication	Hepatocellular Carcinoma
Lead phase	Phase 2
Active trials	5
Collaborator trials	9

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06679985	Phase 2	Active, not recruiting	Sponsor	CHRS	—	Hepatocellular Carcinoma	2H 2026
NCT05635643	Phase 1	Active, not recruiting	Sponsor	CHRS	—	Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma	—
NCT06657144	Phase 1	Recruiting	Sponsor	CHRS	—	Metastatic Solid Tumor; Advanced Solid Tumor	—
NCT06389526	Phase 1	Not yet recruiting	Sponsor	CHRS	—	Advanced or Metastatic Solid Tumors	—
NCT06457503	Not disclosed	Recruiting	Sponsor	CHRS	—	Nasopharyngeal Cancer Recurrent	—
NCT05479045	Phase 2	Not yet recruiting	Collaborator	Georgetown University	—	Ovarian Cancer Stage IV; Ovarian Cancer Stage III; Ovarian Cancer Stage 3	—
NCT06975293	Phase 2	Recruiting	Collaborator	STORM Therapeutics LTD	—	Solid Tumor; Sarcoma; Leiomyosarcoma	—
NCT07214987	Phase 2	Recruiting	Collaborator	Massachusetts General Hospital	—	Squamous Cell Carcinoma; Head and Neck Cancer Squamous Cell Carcinoma; Head and Neck Cancer	—
NCT06940180	Phase 2	Recruiting	Collaborator	Dana-Farber Cancer Institute	—	Sinonasal Cancer; Paranasal Sinus Neoplasms; Squamous Cell Carcinoma	—
NCT07281716	Phase 2	Recruiting	Collaborator	Dan Feng	—	Metastatic Microsatellite Stable Colorectal Carcinoma	—
NCT07277322	Phase 2	Recruiting	Collaborator	Dan Feng	—	Metastatic Colorectal Cancer; Liver Metastases	—
NCT07423078	Phase 2	Recruiting	Collaborator	Matthew Spector	—	Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (; Locally Advanced Laryngeal Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 9 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 14 active trials for Coherus Oncology, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	10,366	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CHRS — Coherus Oncology Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders